Dr. Jim Yong Kim elected as President of the World Bank
On Monday, April 16, 2012, the Executive Board of the World Bank Group named Dr. Jim Yong Kim as its next president. Dr. Kim will assume the role on July 1, succeeding the Bank’s current president, Robert Zoellick. ACTION Director Kolleen Bouchane issued the following statement in response.
ACTION Celebrates Nomination of Dr. Jim Kim to Head the World Bank
ACTION and ACTION Partners
ACTION is thrilled with the nomination of Dr. Jim Yong Kim to head the World Bank. Jim Kim possesses a deep commitment to addressing the political, social, and economic barriers to a more equitable and humane world.
This World TB Day, Global Fund Emergency Donor Meeting Critical for Continued TB Successes
ACTION and ACTION Partners
March 22, 2012 - This World Tuberculosis (TB) Day, ACTION partners around the world will commemorate the day with their attention fixed squarely on world leaders and the need to end the funding crisis of the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Global Fund Welcomes $340 Million Contribution by Japan
The Global Fund to Fight AIDS, Tuberculosis and Malaria
Geneva – The Global Fund to Fight AIDS, Tuberculosis and Malaria today welcomed a $340 million contribution by Japan, the highest amount that Japan has ever made in 10 years of vigorous support for the Global Fund. Japan is now making its first payment of US$ 216 million for its 2012 contribution.
Fund to Fight Key Diseases Running Low
Providence Journal
March 1, 2012
Fund to fight key diseases running low
Richard Feachem
San Francisco -- A study just published in the Lancet, a British medical journal, found that malaria killed 1.2 million people in 2010. That is nearly double the World Health Organization's official estimate.
Compounding this tragic news is that the Global Fund to Fight AIDS, Tuberculosis and Malaria - the largest and arguably the most effective financier of malaria control - is running out of money. It has suspended new grants until 2014 - grants that would have provided millions of families with protective bed nets, life-saving medicines and vital health-care services.
NIH to Join Multi-center Clinical Trial of New Tuberculosis Vaccine
Aeras
Aeras announces today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health (NIH), has joined as a partner for a Phase II proof-of-concept clinical trial of a tuberculosis vaccine candidate jointly developed by Aeras and Dutch biopharmaceutical company Crucell.
Zambia-based CITAM+, a Community Initiative for TB, HIV/AIDS & Malaria, Joins ACTION Partnership
ACTION is excited to announce that Zambia-based Community Initiative for TB, HIV/AIDS & Malaria (CITAM+) has joined the ACTION partnership. With the addition of CITAM+, ACTION now consists of nine advocacy organizations based around the world that are dedicated to empowering ordinary people to become sophisticated advocates who profoundly affect their country's political process in order to improve health and save lives.
ACTION partners selected to serve on new Global Fund for AIDS, TB, and Malaria Committees
ACTION.org
ACTION is excited to announce that two members of the ACTION partnership, Joanne Carter, Executive Director of RESULTS Educational Fund, and Allan Ragi, Executive Director of the Kenya AIDS NGO Consortium, have been appointed to serve on newly created Global Fund committees. Joanne will act as the Developed Country NGO representative on the Strategy, Investment and Impact Committee (SIIC), while Allan will be the Developing Country NGOs representative on the Finance and Operational Performance Committee (FOPC).
AIDS 2012: Submit A Workshop Proposal
In July 2012 tens of thousands of HIV researchers, policy makers, and advocates will attend the 19th International AIDS Conference in Washington, D.C. We urge you to submit proposals for workshops that will bring TB-HIV to the forefront of the conference agenda.
AIDS 2012: Call for Abstracts
In July 2012 tens of thousands of HIV researchers, policy makers, and advocates will attend the 19th International AIDS Conference in Washington, D.C. We invite you to submit abstracts for symposia that will bring TB-HIV to the forefront of the conference agenda.
